PTPN11 and hepatocellular carcinoma: Although SHP2 has been widely recognized as an oncogenic driver in a variety of malignancies, SHP2 can also function as a tumor suppressor in hepatocellular carcinoma, esophageal squamous cell cancer, and cartilage tumors23–25,47.